Liver Transplant CGM
This investigator initiated study aims to describe continuous glucose monitoring (CGM)
based glycemic metrics after discharge from liver transplant and assess relationship with
glycemic metrics and liver transplant outcomes.
Age: 18 years - 66+
Gender: All
Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant
A single institution, single arm, two-cohort feasibility trial to evaluate the
combination of locoregional Y^90 therapy with systemic atezolizumab and bevacizumab, in
participants presenting with hepatocellular carcinoma (HCC) 1) within Milan Criteria (MC)
with AFP ≥...
Age: 18 years - 66+
Gender: All
Guerbet Liver Fibrosis
The goal of this study is to assess the value of liver dynamic contrast-enhanced magnetic
resonance imaging (DCE-MRI) and texture analysis post gadopiclenol for liver fibrosis
staging, in comparison with MR elastography, T1 mapping, ultrasound elastography and
blood ...
Age: 18 - 89 years
Gender: All
Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND)
The purpose of this study is to determine whether the investigational treatment
(maralixibat) is safe and effective in pediatric and adult participants who have
cholestatic liver disease with pruritus that has been refractory to other therapies, and
who have no other...
Age: 6 months - 66+
Gender: All
High Fructose Diet, the Gut Microbiome, and Metabolic Health
Americans commonly consume excess amounts of dietary fructose. Added fructose has been
shown to have an adverse impact on metabolic health, including increased insulin
resistance and type 2 diabetes (T2D) risk. However, the mechanisms that link dietary
fructose and m...
Age: 25 - 45 years
Gender: All
miroliverELAP® for the Treatment of Acute Liver Failure: A Phase 1 Trial
The clinical trial will assess the safety of miroliverELAP for the treatment of acute
liver failure, severe acute alcohol-associated hepatitis, or acute on chronic liver
failure. miroliverELAP is an external liver assist combination product consisting of a
single-use...
Age: 18 - 80 years
Gender: All
Expanding Liver Transplant Immunosuppression Minimization Via Everolimus
This is a study to determine the safety, efficacy, and tolerability of taking away the
anti-rejection medicine, tacrolimus, in liver transplant recipients in conjunction with
everolimus monotherapy to preserve renal function. Two hundred - seventy (270) subjects
will...
Age: 18 years - 66+
Gender: All
An Open-label Study to Investigate ECUR-506 in Male Babies Less Than 9 Months of Age With Neonatal Onset OTC Deficiency
Ornithine Transcarbamylase (OTC) deficiency, the most common urea cycle disorder, is an
inherited metabolic disorder caused by a genetic defect in a liver enzyme responsible for
detoxification of ammonia. Individuals with OTC deficiency can build-up excess levels of
...
Age: 24 hours - 7 months
Gender: Male
A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis
The purpose of this study is to assess the safety of atezolizumab and bevacizumab, or
atezolizumab alone, as first-line treatment in participants with unresectable, locally
advanced or metastatic hepatocellular carcinoma (HCC) with Child-pugh B7 or B8 cirrhosis.
Age: 18 years - 66+
Gender: All
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
To Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients with Primary
Biliary Cholangitis (PBC) and Compensated Cirrhosis.
Age: 18 years - 66+
Gender: All
A Study of NST-6179 in Subjects With Intestinal Failure-Associated Liver Disease (IFALD).
This is a phase 2a, multicenter, randomized, double-blind, placebo-controlled study to
evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of
NST-6179 in subjects with intestinal failure-associated liver disease (IFALD) receiving
paren...
Age: 16 years - 66+
Gender: All
Diversity and Inclusion in Research Underpinning Prevention and Therapy Trials
This proposal brings together multidisciplinary teams from four New York City
institutions charged with reducing cancer disparities that affect approximately two
million people residing in some of the most diverse and underserved communities in the
United States. The...
Age: 21 years - 66+
Gender: All
ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk
The primary objective is to assess overall sensitivity and specificity of Oncoguard™
Liver for hepatocellular cancer (HCC) detection in a surveillance population.
Age: 18 years - 66+
Gender: All
Bridge to HOPE: Hypothermic Oxygenated Perfusion Versus Cold Storage Prior to Liver Transplantation
This is a prospective, multi-center, controlled, randomized, pivotal study to evaluate the
safety and effectiveness of the VitaSmart Liver Machine Perfusion System by comparing
clinical outcomes in patients undergoing liver transplantation with ex-vivo liver
prese...
Age: 18 years - 66+
Gender: All
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
A 52-Week, Multi-center, Open-label, Active Treatment Extension Study to Evaluate Safety and
Tolerability of Once Daily, Oral Administration of Resmetirom (MGL-3196)
Age: 18 years - 66+
Gender: All
TReatment for ImmUne Mediated PathopHysiology
TReatment for ImmUne Mediated PathopHysiology (TRIUMPH) is a multi-center, three arm,
randomized, controlled trial of immunosuppressive therapy for children with acute liver
failure. The study will determine if suppressing inflammatory responses with either
corticost...
Age: 1 year - 18 years
Gender: All
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver
fibrosis histological stage F2 or F3
Age: 18 years - 66+
Gender: All
Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs
Management of ACLF is mainly supportive. The poor outcomes lead physicians to consider
liver transplantation as an option, even if controversial. In sicker recipients, LT
results in immediate survival, but poor medium-term survival rates in some studies. The
scarcity...
Age: 18 - 80 years
Gender: All
Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study
This phase II trial investigates how well lisinopril may work in preventing the
progression of non-alcoholic fatty liver disease (NAFLD). NAFLD is a condition where
there is an accumulation of fatty cells in the liver. NAFLD increases a person's risk of
developing li...
Age: 18 years - 66+
Gender: All
Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study
This phase II trial investigates how well lisinopril may work in preventing the progression of non-alcoholic fatty liver disease (NAFLD). NAFLD is a condition where there is an accumulation of fatty cells in the liver. NAFLD increases a person's risk of developing liver...
Age: 18 years - 66+
Gender: All